Communiqués Isofol Medical AB

Actions

ISOFOL

SE0009581051

Produits pharmaceutiques

Temps Différé Nasdaq Stockholm 13:53:44 08/10/2026			Varia. 5j.	Varia. 1 janv.
0,7640 ^SEK	+0,13%		+0,53%	+4,80%

25/08	Isofol Medical : Redeye fixe une nouvelle valeur intrinsèque à 1,70 couronne	FW
25/08	Isofol Medical AB (publ) publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

22/09	Isofol to present at upcoming investor meetings	AQ
25/08	Isofol Medical (Q2 Review): Approaching the transition into phase II	AQ
25/08	Isofol Medical AB (publ) publishes interim report, January – June 2026	AQ
24/08	Isofol expands the number of study sites to accelerate patient recruitment in cancer study	AQ
08/07	Isofol initiates last dose cohort in ongoing phase Ib study with arfolitixorin	AQ
19/05	Bulletin from annual general meeting in Isofol Medical AB (publ) held on 19 May, 2026	AQ
19/05	Isofol Medical (Q1 Review): Tailwind despite slower recruitment	AQ
19/05	Isofol Medical : Interim Report Q1 2026 (Press Release)	PU
19/05	Isofol Medical AB (publ) publishes interim report, January – March 2026	AQ
30/04	New number of shares and votes in Isofol	AQ
15/04	Notice to attend the Annual General Meeting held on May 19, 2026 in Isofol Medical AB (publ)	AQ
15/04	Isofol optimizes the design of its phase Ib/II study following new regulatory approval	AQ
10/04	Isofol Medical : Corporate governance report 2025, special printing from the annual report 2025, pages 29-37	PU
10/04	Isofol Medical : Annual Report 2025 (Report)	PU
10/04	Isofol Medical : Annual Report 2025 (Press Release)	PU
10/04	Isofol Medical AB (publ) publishes annual report and corporate governance report for 2025	AQ
31/03	Isofol receives gross proceeds of 18.9 MSEK in connection with the exercise of warrants and guarantee commitments for warrants of series TO1, and resolves on a directed share issue	AQ
18/03	Isofol secures license rights for arfolitixorin in autism	AQ
13/03	The subscription price for warrants of series TO1 in Isofol has been set at SEK 0.48 and the exercise period commences on 16 March 2026	AQ
11/03	Isofol receives top guarantee commitment and letters of intent corresponding to 42 percent of upcoming warrant exercise	AQ
09/03	Isofol’s Nomination Committee proposes election of Christian Haglund as new Board Director	AQ
03/03	Isofol presents at investor meetings in March	AQ
24/02	Isofol provides update on the ongoing phase Ib/II clinical study of arfolitixorin	AQ
19/02	Isofol Medical (Q4 Review): Translational year ahead	AQ
18/02	Isofol Medical : Year-end Report Q4 2025 (Press Release)	PU